The Immunogenicity and Safety of Inactivated influenza virus vaccine in clinically cured leprosy patient in China

Inactivated influenza virus vaccine in clinically cured leprosy patient in China

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019602

Enrollment

Unknown

Registered

2018-11-19

Start date

2017-11-01

Completion date

Unknown

Last updated

2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influence

Interventions

leprosy cured:vaccinination

staff:vaccinantion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Wuhan leprosy hospital cured leprosy survivors or staff; (2) Older than 18 years old; (3) The signing of the informed consent.

Exclusion criteria

Exclusion criteria: (1) The recent 2 weeks have a fever, other vaccine, or aspirin use; (2) In the acute infection period; (3) The vaccine composition has a history of allergies; (4) Severe cardiovascular disease; (5) Taboo disease can lead to muscle injection; (6) Other information clinician is not suitable for vaccination.

Design outcomes

Primary

Measure	Time frame
seroconversion rate;	—

Secondary

Measure	Time frame
cytokine level;	—

Countries

China

Contacts

Public ContactQuan Hu

Wuhan Institution of Dermatology and Venerology

powerhu21@yahoo.com+86 15927436898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026